The global cancer monoclonal antibodies (mAbs) market , valued at $55.6 billion in 2021, is projected to reach $106.8 billion by 2031, growing at a CAGR of 7% from 2022 to 2031. This exponential ...

The story of monoclonal antibodies is a testament to the transformative power of scientific innovation combined with strategic business decisions. Monoclonal antibodies (mAbs) are lab-made proteins ...

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

People with autoimmune skin diseases had significantly better cancer survival outcomes than others. Survival benefits were ...

The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Hummingbird Biosciences could one day feather its nest with up to $290 million if its decision to license a phase 2-ready ...

Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...

Preclinical studies suggest ivermectin may be effective against some cancer cell lines in high doses, Johnson said. In a 2021 ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Accord Healthcare’s Henlius-partnered Hetronifly ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

The Global Monoclonal Antibody Therapeutics Market is valued at approximately USD 205.09 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.0% over the forecast ...